Assays In-Depth Focus 2017
HTS can be carried out in a number of formats, ranging from simple biochemical (target-based) to whole animal screening assay formats. Horst Flotow, from Hit Discovery Constance, discusses the benefits and practicalities of, and recent progress in, whole animal screening. Madhu Lal-Nag, National Center for Advancing Translational Sciences, and Anton Simeonov, National Institutes of Health (NIH), explain how 3-D models can be used in HTS, and lead to a significant decrease in the attrition of drug failure rates in clinical trials…
Included in this Assays In-Depth Focus:
- Whole animal screening: back to the future
Horst Flotow, Hit Discovery Contance (HDC) GmbH
- Application Note: Thermo Scientific
- High-throughput screening platforms incorporating physiologically relevant 3-D models
Madhu Lal-Nag, National Center for Advancing Translational Sciences (NCATS) and Anton Simeonov, National Institutes of Health (NIH)
This Assays In-Depth Focus is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!